Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2′-deoxycytidine

被引:43
作者
Cecconi, D
Astner, H
Donadelli, M
Palmieri, M
Missiaglia, E
Hamdan, M
Scarpa, A
Righetti, PG
机构
[1] Univ Verona, Dept Agr & Ind Biotechnol, I-37134 Verona, Italy
[2] Univ Verona, Dept Neurol & Visual Sci, Biochem Sect, I-37134 Verona, Italy
[3] Univ Verona, Dept Pathol, Sect Anatom Pathol, I-37134 Verona, Italy
[4] GlaxoSmithKline, Verona, Italy
关键词
ductal carcinomas; pancreatic tumors; proteomics;
D O I
10.1002/elps.200305724
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A pancreatic adenocarcinoma cell line (PaCa44), which contains, among other alterations , a methylated p16 promoter, was treated with a chemoterapeutic agent, 5-aza-2'deoxycytidine (DAC), in order to evaluate the effect of this drug on cell growth and protein expression. Cell proliferation was strongly inhibited by a 24 h DAC treatment and this inhibition lasted for at least 10 days. Master maps of control and treated PaCa44 cells were generated by analysis with the PDQuest software. The comparison between such maps showed up- and downregulation of 45 polypeptide chains, of which 32 were downregulated and 13 upregulated, out of a total of 700 spots detected by a medium-sensitivity stain, micellar Coomassie Brilliant Blue. Fingerprinting by mass spectrometry analysis enabled the identification of 36 of these spots. Among the major changes in DAC-treated cells: cofilin and profilin 1 are silenced; coactosin, peptidyl-propyl cis-trans isomerase A and cystatin B are decreased by 22, 16- and 15-fold, respectively; stress-70 protein, superoxide dismutase and protein disulfide isomerase A3 are increased by 13-, 11 -, and 5-fold, respectively. The significance of some of these major changes is discussed.
引用
收藏
页码:4291 / 4303
页数:13
相关论文
共 51 条
  • [1] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES
    ALMOGUERA, C
    SHIBATA, D
    FORRESTER, K
    MARTIN, J
    ARNHEIM, N
    PERUCHO, M
    [J]. CELL, 1988, 53 (04) : 549 - 554
  • [2] Histone acetylation and cancer
    Archer, SY
    Hodin, RA
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1999, 9 (02) : 171 - 174
  • [3] FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA
    CALDAS, C
    HAHN, SA
    DACOSTA, LT
    REDSTON, MS
    SCHUTTE, M
    SEYMOUR, AB
    WEINSTEIN, CL
    HRUBAN, RH
    YEO, CJ
    KERN, SE
    [J]. NATURE GENETICS, 1994, 8 (01) : 27 - 32
  • [4] Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy
    Calkins, CC
    Sameni, M
    Koblinski, J
    Sloane, BF
    Moin, K
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1998, 46 (06) : 745 - 751
  • [5] Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A
    Cecconi, D
    Scarpa, A
    Donadelli, M
    Palmieri, M
    Hamdan, M
    Astner, H
    Righetti, PG
    [J]. ELECTROPHORESIS, 2003, 24 (11) : 1871 - 1878
  • [6] Cullen JJ, 2003, CANCER RES, V63, P1297
  • [7] Annexin 1 expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin IIISV40 T large antigen transgenic mice
    de Coupade, C
    Gillet, R
    Bennoun, M
    Briand, P
    Russo-Marie, F
    Solito, E
    [J]. HEPATOLOGY, 2000, 31 (02) : 371 - 380
  • [8] Ebert E, 1997, ADV EXP MED BIOL, V421, P259
  • [9] Cancer cell motility - On the road from c-erbB-2 receptor steered signaling to actin reorganization
    Feldner, JC
    Brandt, BH
    [J]. EXPERIMENTAL CELL RESEARCH, 2002, 272 (02) : 93 - 108
  • [10] Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters
    Fritz, G
    Brachetti, C
    Bahlmann, F
    Schmidt, M
    Kaina, B
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (06) : 635 - 644